A Versatile Plasma Membrane Engineered Cell Vehicle for Contact‐Cell‐Enhanced Photodynamic Therapy

In this paper, a plasma membrane engineering approach is reported for tumor targeting drug delivery and contact‐cell‐enhanced photodynamic therapy (“CONCEPT”) by anchoring functionalized conjugates to cell vehicles. The membrane anchoring conjugates are comprised of a positively charged tetra‐argini...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2017-03, Vol.27 (12), p.np-n/a
Main Authors: Li, Shi‐Ying, Qiu, Wen‐Xiu, Cheng, Hong, Gao, Fan, Cao, Feng‐Yi, Zhang, Xian‐Zheng
Format: Article
Language:English
Subjects:
Anchoring
Anchors
Biocompatibility
cell vehicles
Conjugates
Drug delivery systems
Erythrocytes
Fluorescein
In vitro methods and tests
Insertion
Lasers
Lysine
Materials science
Membranes
Photodynamic therapy
plasma membrane
Side effects
Stem cells
Toxicity
tumor targeting
Tumors
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this paper, a plasma membrane engineering approach is reported for tumor targeting drug delivery and contact‐cell‐enhanced photodynamic therapy (“CONCEPT”) by anchoring functionalized conjugates to cell vehicles. The membrane anchoring conjugates are comprised of a positively charged tetra‐arginine peptide sequence, a palmitic‐acid‐based membrane insertion moiety, and a lysine linker whose ε‐amine is modified with camptothecin (CPT), protoporphyrin IX (PpIX), or fluorescein (FAM). The amphipathic CPT, PpIX, or FAM conjugates (short as aCPT, aPpIX, or aFAM, respectively) can easily and steadily anchor or coanchor on the cell membrane of RAW264.7 cells (short as RCs), red blood cells, or mesenchymal stem cells. After anchoring aPpIX in RC cells, the tumor targeting ability and therapeutic effect of aPpIX‐anchored RC cells (short as aPRCs) is demonstrated in vitro and in vivo. Importantly, aPRCs exhibit the “CONCEPT” effect, which can enhance the therapeutic efficacy and reduce side effects at the single cell level. Due to the good tumor‐targeting ability, aPRCs can efficiently inhibit the tumor growth with no systemic toxicity after photoirradiation by photodynamic therapy. A versatile plasma‐membrane‐engineered cell vehicle is developed for tumor targeting drug delivery and contact‐cell‐enhanced photodynamic therapy. This versatile cell vehicle can facilitate the development of personalized treatment for simultaneous tumor theranostics and combination therapy in a more safe way.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.201604916